AP Biosciences Inc (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
177.00
-1.50 (-0.84%)
At close: Feb 26, 2026
216.64%
Market Cap 15.15B
Revenue (ttm) n/a
Net Income (ttm) -447.41M
Shares Out 85.57M
EPS (ttm) -5.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 787,742
Average Volume 376,259
Open 180.00
Previous Close 178.50
Day's Range 175.00 - 182.50
52-Week Range 36.30 - 197.50
Beta 0.24
RSI 60.95
Earnings Date Mar 20, 2026

About AP Biosciences

AP Biosciences Inc researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinical... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.